Navigation Links
Janssen and Johnson & Johnson to Provide Webcast Presentation of Simeprevir Phase 3 Clinical Data Presented at The International Liver Congress of the European Association for the Study of the Liver (EASL)
Date:5/2/2013

NEW BRUNSWICK, N.J., May 2, 2013 /PRNewswire/ -- Janssen R&D Ireland (Janssen) and Johnson & Johnson (NYSE: JNJ) will provide a pre-recorded webcast for investors and other interested parties on Friday, May 3, at approximately 8:30 a.m., Eastern Time, to discuss simeprevir phase 3 clinical data presented at The International Liver Congress of the European Association for the Study of the Liver (EASL).

A pre-recorded webcast featuring management from Janssen will provide an overview of results from the phase 3 QUEST -1 and QUEST-2 studies of the investigational protease inhibitor simeprevir (TMC435) administered once daily in combination with pegylated interferon and ribavirin in treatment-naive genotype 1 chronic hepatitis C patients.

The webcast/podcast can be accessed by visiting the Johnson & Johnson website at www.investor.jnj.com and clicking on "Webcasts/Presentations."

 

 


'/>"/>
SOURCE Johnson & Johnson
Copyright©2012 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. Findings from Two Phase 3 Studies of Janssens Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Genotype 1 Chronic Hepatitis C Patients
2. Janssen Submits New Drug Application to U.S. FDA for Simeprevir (TMC435) for Combination Treatment of Adult Patients with Genotype 1 Chronic Hepatitis C
3. Janssen Launches EXPLORER, Global Cardiovascular Research Program, Beginning with Five New Studies in Patients with Unmet Medical Needs
4. Janssen Pharmaceutica, NV, Funds New Global Mental Health Scholarships as Part of Its Healthy Minds Program
5. Janssen Neuroscientists and Colleagues Challenge Healthcare Industry to Create Integrated Approaches to Healthcare Innovation in Newly Published Article
6. Janssen Labs at San Diego Expands to Add Concept Lab and Open Collaboration Space to Accommodate Individual Entrepreneurs and Additional Life Science Start-Ups
7. Janssen Research & Development Submits New Drug Application to U.S. FDA for Canagliflozin/Metformin Fixed-Dose Combination Therapy to Treat Patients with Type 2 Diabetes
8. Janssen Research & Development Announces Establishment of Global Cross-Pharmaceutical Clinical Trial Investigator Databank
9. Efficacy and Safety Data from Phase 2B Trials of Janssens Simeprevir in Hepatitis C Patients with Advanced Fibrosis of the Liver Presented at Annual Meeting of the American Association for the Study of Liver Diseases
10. Janssen and Johnson & Johnson to Provide Webcast Presentation of Immunology Pivotal Phase 3 Data Being Presented at the American College of Rheumatology Annual Meeting
11. Janssen Announces Collaboration with Vertex on Phase 2 Study to Investigate an All-Oral Regimen of Simeprevir (TMC435) and VX-135 for Treatment of Hepatitis C
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/5/2016)... Dec. 5, 2016   Mallinckrodt Pharmaceuticals (NYSE: ... company, today announced that it received a perfect score ... (CEI), a national benchmarking survey and report on corporate ... transgender (LGBT) workplace equality, administered by the Human Rights ... major U.S. businesses which also earned top marks this ...
(Date:12/5/2016)... , Dec. 5, 2016 Special purpose needles are ... such as fluid and cells from organs or lumps and ... and sizes. The global market for special purpose needles is ... In terms of revenue, the global special purpose needles market ... the forecast period (2016–2026) and is expected to be valued ...
(Date:12/5/2016)...   Lexicon Pharmaceuticals, Inc. (Nasdaq: ... 2 clinical study of sotagliflozin, a dual SGLT1 and ... the leading global organization funding type 1 diabetes research. ... trial, which randomized a total of 87 patients, was ... dose of sotagliflozin compared to a placebo control in ...
Breaking Medicine Technology:
(Date:12/5/2016)... , ... December 05, 2016 , ... ... Plastic Surgery, is excited to announce the arrival of the newest Sciton laser ... with the ability to use tunable non-ablative and ablative wavelengths for exceptional results. ...
(Date:12/5/2016)... ... December 05, 2016 , ... SyncDog, Inc., the leading ... magazine, a leading online tech news platform connecting technology innovators with news, experience, ... explores the state of enterprise mobility security today, and how the SyncDog SentinelSecure™ ...
(Date:12/5/2016)... ... 05, 2016 , ... Worldwise ®, a leading consumer ... kathy ireland® Worldwide for five additional years, announced by Kevin Fick, Worldwise CEO. ... agreement three years ago to design and develop the kathy ireland® Loved Ones™ ...
(Date:12/5/2016)... ... December 05, 2016 , ... Physicians Education Resource®, ... International Congress on Hematologic Malignancies®: Focus on Leukemias, Lymphomas, and Myeloma, on February ... are honored to have Amy E. Herman present at this year’s conference, her ...
(Date:12/5/2016)... , ... December 05, 2016 , ... BSI and Brenntag ... United States and Canada for distribution of their natural fruits and beverage ... is an exciting addition to our Life Sciences product portfolio,” said Steve Brauer, ...
Breaking Medicine News(10 mins):